Despite encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from managed care entities. These insurers are frequently creating limitations to reimbursement, such as high price restrictions and prior authorization that limit user opportunity. I… Read More